OLUX® (clobetasol propionate) Foam, 0.05%
OLUX Foam contains clobetasol propionate, USP, a synthetic corticosteroid, for topical dermatologic use. Clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity.
OLUX Foam is a super-potent topical corticosteroid indicated for short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp, and for short-term topical treatment of mild to moderate plaque-type psoriasis of non-scalp regions excluding the face and intertriginous areas.
Treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. In a controlled pharmacokinetic study, some subjects experienced reversible suppression of the adrenals following 14 days of OLUX Foam therapy (See ADVERSE REACTIONS).
Use in children under 12 years of age is not recommended.
Media Articles Related to Olux (Clobetasol Topical)
Source: MedicineNet Itch Specialty [2014.08.27]
Title: Seborrheic Dermatitis
Category: Diseases and Conditions
Created: 3/16/2012 5:47:00 PM
Last Editorial Review: 8/27/2014 12:00:00 AM
Source: MedicineNet Otitis Externa Specialty [2014.04.23]
Title: Atopic Dermatitis
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 4/23/2014 12:00:00 AM
Atopic Eczema (Atopic Dermatitis) Quiz: Test Your Skin Disorders IQ
Source: MedicineNet mometasone Specialty [2013.12.20]
Title: Atopic Eczema (Atopic Dermatitis) Quiz: Test Your Skin Disorders IQ
Category: MedicineNet Quiz
Created: 3/20/2012 12:50:00 PM
Last Editorial Review: 12/20/2013 12:24:14 PM
Eczema (Atopic Dermatitis) Pictures Slideshow: Causes, Symptoms and Treatment
Source: MedicineNet Skin Test For Allergy Specialty [2013.12.18]
Title: Eczema (Atopic Dermatitis) Pictures Slideshow: Causes, Symptoms and Treatment
Created: 3/26/2012 12:00:00 AM
Last Editorial Review: 12/18/2013 12:00:00 AM
Picture of Atopic Dermatitis
Source: MedicineNet pimecrolimus Specialty [2010.12.15]
Title: Picture of Atopic Dermatitis
Created: 12/15/2010 6:54:00 PM
Last Editorial Review: 12/15/2010 6:54:33 PM
Published Studies Related to Olux (Clobetasol Topical)
A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05%
clobetasol propionate ointment in discoid lupus erythematosus by modified
cutaneous lupus erythematosus disease area and severity index. 
CONCLUSION: The present study proved the efficacy of twice-daily tacrolimus and
A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0.1% vs. clobetasol propionate 0.05% in childhood vitiligo. [2011.09]
BACKGROUND: Both clobetasol propionate 0.05% (CP 0.05%) and tacrolimus 0.1% (T 0.1%) ointments have been shown to be efficacious and safe in treating vitiligo in the paediatric population. OBJECTIVES: To assess efficacy and safety of these two therapies compared with each other and with placebo... CONCLUSIONS: Both CP 0.05% and T 0.1% ointments offer similar benefit in paediatric vitiligo, both facial and nonfacial. The facial lesions responded faster than the nonfacial ones. (c) 2011 The Authors. BJD (c) 2011 British Association of Dermatologists.
Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial. [2011.08]
BACKGROUND: Clobetasol propionate 0.05% spray is available for treating moderate-to-severe plaque psoriasis; however, there is limited information with plaque psoriasis of the scalp. OBJECTIVE: Evaluate the efficacy, safety, and quality-of-life impact of clobetasol propionate 0.05% spray in patients with moderate to severe plaque psoriasis of the scalp... CONCLUSION: Treatment with clobetasol propionate 0.05% spray for up to four weeks is effective and well tolerated for moderate-to-severe plaque psoriasis of the scalp.
Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet A therapy in palmoplantar psoriasis. [2011.08]
AIM: Palmoplantar psoriasis (PPP) produces significant morbidity and requires prompt treatment. Topical agents form the mainstay of therapy. We compared the efficacy and side-effect profile of a steroid/coal-tar combination with topical psoralen and solar ultraviolet A (PUVAsol) in PPP... CONCLUSION: Both treatments had comparable efficacy. In both groups, patients experienced 'good improvement' after 16 weeks of therapy. (c) The Author(s). CED (c) 2011 British Association of Dermatologists.
Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0.05% combined with ketoconazole shampoo 2%: a randomized, controlled study. [2011.07]
BACKGROUND: Topical antifungals and corticosteroids are the mainstay of treatment for seborrhoeic dermatitis. The short-contact clobetasol propionate 0.05% shampoo (CP) is an efficacious and safe once-daily treatment for scalp psoriasis. OBJECTIVES: To evaluate the efficacy and safety of CP alone and combined with ketoconazole shampoo 2% (KC) in the treatment of moderate to severe scalp seborrhoeic dermatitis... CONCLUSIONS: The combination therapy of twice-weekly CP alternating with twice-weekly KC provided significantly greater efficacy than KC alone and a sustained effect in the treatment of moderate to severe scalp seborrhoeic dermatitis. (c) 2011 The Authors. BJD (c) 2011 British Association of Dermatologists 2011.
Clinical Trials Related to Olux (Clobetasol Topical)
A Comparison Between Clobetasol Propionate 0.05% (Clobex«) Spray and Clobetasol Propionate 0.05% (Olux«) Foam [Completed]
Clobetasol for Oral Graft-Versus-Host Disease [Recruiting]
- Oral graft-versus-host disease (GVHD) is a possible complication of bone marrow
transplants. It is the result of the donor cells trying to attack the recipient's body.
Symptoms include dry mouth, sensitivity and pain when tasting certain spices and flavors,
and painful swallowing. Steroids are a possible effective treatment for GHVD, but they can
cause side effects when given as pills or injections. Steroids given in a cream or rinse
form, applied directly to the site of the symptoms, can have fewer side effects. However,
their effectiveness as a rinse has not been tested in the mouth. Researchers want to see if
a steroid called clobetasol can be used as a mouth rinse to treat oral GHVD.
- To see if a clobetasol rinse is a safe and effective treatment for oral graft-versus-host
- Individuals at least 12 years of age who have oral GHVD and are not allergic to
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will be collected. They will also have an oral exam, a mouth tissue biopsy, and
other tests before starting the study drug.
- Participants will be separated into two groups. One group will receive clobetasol; the
other will have a placebo liquid.
- Participants will rinse their mouths with the study liquid three times a day after
meals for 2 weeks.
- After 2 weeks, participants will have another study visit with blood tests and other
- After the study visit, all participants will start to use the clobetasol rinse. Those
who originally had clobetasol will use the rinse for another 2 weeks. Those who
originally had a placebo will use the rinse for 4 weeks.
- Participants will have a follow-up exam after the end of treatment.
Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis [Recruiting]
This is a 12-week, open-label, pilot trial evaluating the efficacy and safety of the
combination of Clobex« spray with excimer laser therapy as the initial treatment of
generalized plaque psoriasis, followed by maintenance therapy with topical Vectical. The
study will be conducted in three distinct periods, namely Period A, Period B, and Period C,
each of 4 weeks duration. During Period A (weeks 1 through 4), patients will use Clobex«
spray twice daily along with excimer laser treatments twice weekly with the Photomedex
XTRAC┬« Velocity machine. The goal of Period A is to achieve PASI 75 in 100% of patients
within four weeks. During Period B (weeks 5 through 8), patients would be treated with
topical Vectical┬« twice daily. Thus, there is a steroid-free interval during which patients
will not be using Clobex┬« spray. The goal of Period B is to maintain the patient's response
using only non-steroid options. During Period C of the study, patients will use Clobex┬«
spray BID and Vectical┬« BID. Period C (weeks 9 through 12) will be a "booster" period in
which the goal is to see if 100% of patients can achieve PASI 90-100. Regarding excimer
laser therapy: all patients will be receiving excimer laser therapy twice weekly for the
first 6 weeks of the study (up to the halfway point) which is 12 excimer laser treatments.
At that point, only those patients achieving
Efficacy, Tolerance and Satisfaction With CLOBEX« Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis [Completed]
Evaluation of the effectiveness of Clobex« Spray, 0. 05% when used as monotherapy or add-on
therapy to existing systemic or topical anti-psoriatic agents.
Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy [Recruiting]
The purpose of this study is to determine whether spironolactone could significantly reduce
cutaneous atrophy due to corticosteroids.